Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK1 | Q13464 | 4/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 8/20 | 0.41 |
| ▸ | AR | P10275 | 1/20 | 0.41 |
| ▸ | RAF1 | P04049 | 2/20 | 0.41 |
| ▸ | BRAF | P15056 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 4/20 | 0.40 |
| ▸ | AURKA | O14965 | 3/20 | 0.40 |
| ▸ | MET | P08581 | 3/20 | 0.40 |
| ▸ | TEK | Q02763 | 3/20 | 0.40 |
| ▸ | ABL1 | P00519 | 2/20 | 0.39 |
| ▸ | LCK | P06239 | 2/20 | 0.39 |
| ▸ | LYN | P07948 | 1/20 | 0.39 |
| ▸ | FGR | P09769 | 1/20 | 0.39 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.39 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2333972 | 1.00 | ROCK1 (0.44) | ROCK1EPHX2ARRAF1BRAF | |
| SCHEMBL26928502 | 0.90 | ROCK1 (0.45) | ROCK1EPHX2ARRAF1BRAF | |
| SCHEMBL26928507 | 0.90 | ROCK1 (0.45) | ROCK1EPHX2ARRAF1BRAF | |
| SCHEMBL30738183 | 0.87 | EPHX2 (0.47) | ROCK1EPHX2ARRAF1BRAF | |
| SCHEMBL2334308 | 0.87 | EPHX2 (0.47) | ROCK1EPHX2ARRAF1BRAF | |
| SCHEMBL2334311 | 0.87 | EPHX2 (0.47) | ROCK1EPHX2ARRAF1BRAF | |
| SCHEMBL3372945 | 0.84 | ROCK1 (0.57) | ROCK1ABL1ROCK2KCNH2 | |
| SCHEMBL30824419 | 0.82 | EPHX2 (0.39) | ROCK1EPHX2RAF1BRAFROCK2 | |
| SCHEMBL26957025 | 0.82 | EPHX2 (0.39) | ROCK1EPHX2RAF1BRAFROCK2 | |
| SCHEMBL30738020 | 0.82 | KDR (0.40) | ROCK1EPHX2ARRAF1BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8796458-B2 | Cyclohexylamine isoquinolone derivatives | SANOFI (FR) | 2014-08-05 | — | — | US | disclosed |
| US-8796458-B2 | Cyclohexylamine isoquinolone derivatives | SANOFI (FR) | 2014-08-05 | — | — | US | disclosed |
| US-8796458-B2 | Cyclohexylamine isoquinolone derivatives | SANOFI (FR) | 2014-08-05 | — | — | US | disclosed |
| US-8609691-B2 | Cyclohexylamin isoquinolone derivatives | SANOFI (FR) | 2013-12-17 | — | — | US | disclosed |
| US-20110251226-A1 | CYCLOHEXYLAMIN ISOQUINOLONE DERIVATIVES | SANOFI-AVENTIS (FR) | 2011-10-13 | — | — | US | disclosed |
| US-20110251226-A1 | CYCLOHEXYLAMIN ISOQUINOLONE DERIVATIVES | SANOFI-AVENTIS (FR) | 2011-10-13 | — | — | US | disclosed |
| EP-1912949-B1 | CYCLOHEXYLAMIN ISOQUINOLONE DERIVATIVES AS RHO-KINASE INHIBITORS | SANOFI SA (FR) | 2011-08-24 | — | — | EP | disclosed |
| US-20080242699-A1 | Rho-kinase and/or Rho-kinase mediated phosphorylation of myosin light chain phosphatase inhibitors; Hypotensive agents; 6-(4-Amino-cyclohexyloxy)-2-(4-methoxy-benzyl)-7-propyl-2H-isoquinolin-1-one | SANOFI-AVENTIS (FR) | 2008-10-02 | — | — | US | disclosed |
| US-20080242699-A1 | Rho-kinase and/or Rho-kinase mediated phosphorylation of myosin light chain phosphatase inhibitors; Hypotensive agents; 6-(4-Amino-cyclohexyloxy)-2-(4-methoxy-benzyl)-7-propyl-2H-isoquinolin-1-one | SANOFI-AVENTIS (FR) | 2008-10-02 | — | — | US | disclosed |
| US-20080242699-A1 | Rho-kinase and/or Rho-kinase mediated phosphorylation of myosin light chain phosphatase inhibitors; Hypotensive agents; 6-(4-Amino-cyclohexyloxy)-2-(4-methoxy-benzyl)-7-propyl-2H-isoquinolin-1-one | SANOFI-AVENTIS (FR) | 2008-10-02 | — | — | US | disclosed |
| EP-1912949-A1 | CYCLOHEXYLAMIN ISOQUINOLONE DERIVATIVES AS RHO-KINASE INHIBITORS | Sanofi-Aventis (FR) | 2008-04-23 | — | — | EP | disclosed |
| WO-2007012422-A1 | CYCLOHEXYLAMIN ISOQUINOLONE DERIVATIVES AS RHO-KINASE INHIBITORS | SANOFI-AVENTIS (DE) | 2007-02-01 | — | — | WO | disclosed |
| WO-2007012422-A1 | CYCLOHEXYLAMIN ISOQUINOLONE DERIVATIVES AS RHO-KINASE INHIBITORS | SANOFI-AVENTIS (DE) | 2007-02-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080242699-A1 | Rho-kinase and/or Rho-kinase mediated phosphorylation of myosin light chain phosphatase inhibitors; Hypotensive agents; 6-(4-Amino-cyclohexyloxy)-2-(4-methoxy-benzyl)-7-propyl-2H-isoquinolin-1-one | MYLK, MYLK2, ROCK1 | ROCK1 3/4885EPHX2 2909/4885AR 4771/4885 |
| US-20110251226-A1 | CYCLOHEXYLAMIN ISOQUINOLONE DERIVATIVES | MYLK2, MYLK, MYLK3 | ROCK1 7/4885EPHX2 2266/4885AR 4815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.